We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
XOMA Corporation | NASDAQ:XOMA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.66 | -2.59% | 24.78 | 23.00 | 26.90 | 25.58 | 24.60 | 25.58 | 8,213 | 01:00:00 |
Levi & Korsinsky announces it has commenced an investigation of Xoma Corporation (NASDAQ: XOMA) concerning possible violations of federal securities laws. The investigation concerns whether Xoma Corporation and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 22, 2015, XOMA announced that a Phase III trial of its treatment gevokizumab for Behcet’s disease in the eye missed the primary endpoint of time to first acute ocular exacerbation. To obtain additional information, go to:
http://zlk.9nl.com/xoma
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150723006143/en/
Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel: 212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
1 Year XOMA Chart |
1 Month XOMA Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions